Cargando…

Sexual, physical, and overall adverse effects in patients treated with 5α-reductase inhibitors: a systematic review and meta-analysis

Postfinasteride syndrome (PFS) is a term coined to characterize a constellation of reported undesirable sexual, physical, and neuropsychiatric side effects. In the present study, we conducted the meta-analysis to demonstrate whether the use of 5α-reductase inhibitors (5ARIs) increases the risk of PF...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jun-Jie, Shi, Xiao, Wu, Ting, Zhang, Meng-Da, Tang, Jin, Yin, Guang-Ming, Long, Zhi, He, Le-Ye, Qi, Lin, Wang, Long
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295476/ https://www.ncbi.nlm.nih.gov/pubmed/34747724 http://dx.doi.org/10.4103/aja202171

Ejemplares similares

Enduring sexual dysfunction after treatment with antidepressants, 5α-reductase inhibitors and isotretinoin: 300 cases
por: Healy, David, et al.
Publicado: (2018)

The Dark Side of 5α-Reductase Inhibitors' Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression
por: Traish, Abdulmaged M., et al.
Publicado: (2014)

Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia
por: Zhang, Jiandong, et al.
Publicado: (2023)

5α-reductase inhibitors impact prognosis of urothelial carcinoma
por: Wang, Chien-Sheng, et al.
Publicado: (2020)

Is There a Link between 5α-Reductase Inhibitors and Hypoglycemia?
por: Jeong, Jin Woo, et al.
Publicado: (2021)

Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide
por: Garcia-Argibay, Miguel, et al.
Publicado: (2022)

Genetic sequencing of a patient with Kallmann syndrome plus 5α-reductase type 2 deficiency
por: Ji, Wen, et al.
Publicado: (2017)

Current Status of 5α-Reductase Inhibitors in Prostate Disease Management
por: Kang, Dong Il, et al.
Publicado: (2013)

Adverse Factors of Treatment Response and Overall Survival in Pediatric and Adult Patients with Pineoblastoma
por: Huo, Xu-Lei, et al.
Publicado: (2020)

Use of 5α-reductase inhibitor and delay in prostate cancer diagnosis and treatment
por: Busato, Wilson F. S.
Publicado: (2020)

α1-Blockers and 5α-Reductase Inhibitors Are the Most Recommended Drugs in Treating Benign Prostatic Hyperplasia: An Evidence-Based Evaluation of Clinical Practice Guidelines
por: Xu, Xiao-Feng, et al.
Publicado: (2020)

PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST
por: Hansson, E K, et al.
Publicado: (2013)

Effect of 5α-reductase inhibitors on the efficiency of thulium:yttrium-aluminium-garnet (RevoLix®) vaporesection for treating benign prostatic hyperplasia
por: Chung, Jae Seung, et al.
Publicado: (2020)

The Risk of Adverse Effects of TNF-α Inhibitors in Patients With Rheumatoid Arthritis: A Network Meta-Analysis
por: He, Bei, et al.
Publicado: (2022)

Computer aided screening of inhibitors to 5-α reductase type 2 for prostate cancer
por: Bhattacharjee, Biplab, et al.
Publicado: (2011)

5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer
por: Robinson, David, et al.
Publicado: (2015)

Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride
por: Kiguradze, Tina, et al.
Publicado: (2017)

Nanostructured Drug Delivery Systems for Targeting 5-α-Reductase Inhibitors to the Hair Follicle
por: Tampucci, Silvia, et al.
Publicado: (2022)

Peripheral Neuroprotective and Immunomodulatory Effects of 5α-Reductase Inhibitors in Parkinson’s Disease Models
por: Poirier, Andrée-Anne, et al.
Publicado: (2022)

Medical therapy for clinical benign prostatic hyperplasia: α1 Antagonists, 5α reductase inhibitors and their combination
por: Shum, Cheuk Fan, et al.
Publicado: (2017)

Thioredoxin Reductase and its Inhibitors
por: Saccoccia, Fulvio, et al.
Publicado: (2014)

Peripheral Blood Biomarkers Predictive of Efficacy Outcome and Immune-Related Adverse Events in Advanced Gastrointestinal Cancers Treated with Checkpoint Inhibitors
por: Zhang, Zhening, et al.
Publicado: (2022)

Bioactivity Focus of α-Cyano-4-hydroxycinnamic acid (CHCA) Leads to Effective Multifunctional Aldose Reductase Inhibitors
por: Zhang, Laitao, et al.
Publicado: (2016)

High Hydrostatic Pressure Inducible Trimethylamine N-Oxide Reductase Improves the Pressure Tolerance of Piezosensitive Bacteria Vibrio fluvialis
por: Yin, Qun-Jian, et al.
Publicado: (2018)

Evolution of Optimized Hydride Transfer Reaction and Overall Enzyme Turnover in Human Dihydrofolate Reductase
por: Li, Jiayue, et al.
Publicado: (2021)

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
por: Huang, Jing, et al.
Publicado: (2020)

5-α reductase inhibitors and prostate cancer prevention: where do we turn now?
por: Hamilton, Robert J, et al.
Publicado: (2011)

Current status of 5α-reductase inhibitors in the management of lower urinary tract symptoms and BPH
por: Gravas, Stavros, et al.
Publicado: (2009)

Association of Treatment With 5α-Reductase Inhibitors and Prostate Cancer Mortality Among Older Adults
por: Kumar, Abhishek, et al.
Publicado: (2019)

Association of 5α-Reductase Inhibitor Prescription With Bladder Cancer Progression in Males in South Korea
por: An, Min Ho, et al.
Publicado: (2023)

Correlation of the gut microbiome and immune-related adverse events in gastrointestinal cancer patients treated with immune checkpoint inhibitors
por: Zhang, Yifan, et al.
Publicado: (2023)

The Predictive Significance of Prognostic Nutritional Index and Serum Albumin/Globulin Ratio on the Overall Survival of Penile Cancer Patients Undergoing Penectomy
por: Song, Wei-Jie, et al.
Publicado: (2022)

In Search of Differential Inhibitors of Aldose Reductase
por: Balestri, Francesco, et al.
Publicado: (2022)

Impact of preoperative 5α-reductase inhibitors on perioperative blood loss in patients with benign prostatic hyperplasia: a meta-analysis of randomized controlled trials
por: Zhu, Yi-Ping, et al.
Publicado: (2015)

Pressure-Regulated Gene Expression and Enzymatic Activity of the Two Periplasmic Nitrate Reductases in the Deep-Sea Bacterium Shewanella piezotolerans WP3
por: Li, Xue-Gong, et al.
Publicado: (2018)

HMG CoA reductase inhibitors (statins) to treat Epstein–Barr virus-driven lymphoma
por: Cohen, J I
Publicado: (2005)

Diagnosis of prostate cancer with magnetic resonance imaging in men treated with 5-alpha-reductase inhibitors
por: Falagario, Ugo G., et al.
Publicado: (2023)

Structure of human steroid 5α-reductase 2 with the anti-androgen drug finasteride
por: Xiao, Qingpin, et al.
Publicado: (2020)

Structure of human steroid 5α-reductase 2 with anti-androgen drug finasteride
por: Xiao, Qingpin, et al.
Publicado: (2020)

Structure-guided design of anti-cancer ribonucleotide reductase inhibitors
por: Misko, Tessianna A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8rqp9ir7jeq3tariuqs85bqlie